Cite
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas
MLA
Dario Neri, et al. “Dose Escalation and Expansion Phase I Studies with the Tumour-Targeting Antibody-Tumour Necrosis Factor Fusion Protein L19TNF plus Doxorubicin in Patients with Advanced Tumours, Including Sarcomas.” European Journal of Cancer (Oxford, England : 1990), vol. 150, Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....530bc72c55f6b6ce7cac26721a6ee751&authtype=sso&custid=ns315887.
APA
Dario Neri, Torsten Kessler, Walter Heindel, Wolfgang E. Berdel, Wolfgang Hartmann, Jan Philipp Hering, Eva Wardelmann, Georg Lenz, Linus Angenendt, Filippo de Braud, Teresa Hemmerle, Andrea Kerkhoff, Sant P. Chawla, Christoph Schliemann, & Andrew F. Berdel. (2021). Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. European Journal of Cancer (Oxford, England : 1990), 150.
Chicago
Dario Neri, Torsten Kessler, Walter Heindel, Wolfgang E. Berdel, Wolfgang Hartmann, Jan Philipp Hering, Eva Wardelmann, et al. 2021. “Dose Escalation and Expansion Phase I Studies with the Tumour-Targeting Antibody-Tumour Necrosis Factor Fusion Protein L19TNF plus Doxorubicin in Patients with Advanced Tumours, Including Sarcomas.” European Journal of Cancer (Oxford, England : 1990) 150 (January). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....530bc72c55f6b6ce7cac26721a6ee751&authtype=sso&custid=ns315887.